Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VanEck Biotech ETF (NQ:BBH)

240.47 +6.43 (+2.75%)
Official Closing Price Updated: 4:15 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VanEck Biotech ETF

< Previous 1 2 Next >
News headline image
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH ↗
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma ↗
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗
VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility. 
Via The Motley Fool
Topics ETFs
PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
Via Stocktwits
News headline image
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗
VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year. 
Via The Motley Fool
Topics ETFs
News headline image
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? ↗
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk. 
Via The Motley Fool
Topics ETFs
News headline image
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees ↗
VHT's diversified portfolio of 411 holdings delivered $1,278 from a $1,000 investment over five years, while its lower expense ratio and higher dividend yield appeal to income investors. 
Via The Motley Fool
Topics ETFs
News headline image
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? ↗
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers. 
Via The Motley Fool
Topics ETFs
News headline image
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? ↗
RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? ↗
Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry. 
Via The Motley Fool
Topics ETFs
News headline image
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
Compare fees, diversification, and risk between these two leading healthcare ETFs. 
Via The Motley Fool
Topics ETFs
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
VanEck Announces Year-End Distributions for VanEck Equity ETFs
From VanEck
Via Business Wire
News headline image
VanEck Announces Year-End Distributions for VanEck Equity ETFs
From VanEck
Via Business Wire
News headline image
VanEck Announces Year-End Distributions for VanEck Equity ETFs
From VanEck
Via Business Wire
News headline image
Time For Gilead Sciences-Heavy ETFs? ↗
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
News headline image
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
News headline image
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
News headline image
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
News headline image
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
News headline image
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗
 
Via Benzinga
News headline image
VanEck Launches Robotics ETF (IBOT)
From VanEck
Via Business Wire
News headline image
US Judge Weighs Nationwide Ban On Abortion Pills ↗
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
News headline image
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗
 
Via Benzinga
News headline image
3 Best Funds for Aggressive Investors ↗
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.